Many of the catabolic changes seen in normal aging, including osteopenia and sarcopenia, have been attributed to the age-related decline in the activity of the hypothalamic growth hormone (GH) insulin-like growth factor-1 (IGF-1) axis ("the somatopause"). However, the concept that GH replacement would benefit aging people finds little support in data obtained from controlled clinical trials. GH does not induce a substantial improvement in bone mass, and therefore, its use in the treatment of postmenopausal osteoporosis does not seem to be appropriate. GH may yet prove to be a useful agent in the management of other clinical syndromes, such as visceral obesity, catabolic conditions and chronic heart failure. The potential benefits of GH treatment in these clinical conditions await sound evidence from future clinical trials.
Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in the elderly: Clinical trial results
Corradi, F.Writing – Review & Editing
;
2002-01-01
Abstract
Many of the catabolic changes seen in normal aging, including osteopenia and sarcopenia, have been attributed to the age-related decline in the activity of the hypothalamic growth hormone (GH) insulin-like growth factor-1 (IGF-1) axis ("the somatopause"). However, the concept that GH replacement would benefit aging people finds little support in data obtained from controlled clinical trials. GH does not induce a substantial improvement in bone mass, and therefore, its use in the treatment of postmenopausal osteoporosis does not seem to be appropriate. GH may yet prove to be a useful agent in the management of other clinical syndromes, such as visceral obesity, catabolic conditions and chronic heart failure. The potential benefits of GH treatment in these clinical conditions await sound evidence from future clinical trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
